These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37153146)

  • 21. Impact of appropriate empirical antibiotics on clinical outcomes in
    Man MY; Shum HP; Li KC; Yan WW
    Hong Kong Med J; 2021 Aug; 27(4):247-257. PubMed ID: 34393109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae.
    Lee JA; Kang CI; Joo EJ; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Ko KS; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):267-73. PubMed ID: 21388296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: First systematic review and meta-analysis from Iran.
    Beigverdi R; Jabalameli L; Jabalameli F; Emaneini M
    J Glob Antimicrob Resist; 2019 Sep; 18():12-21. PubMed ID: 30685458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
    Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
    Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of extended-spectrum β-lactamase on clinical outcome and medical cost in patients with bloodstream infection due to Klebsiella pneumoniae].
    Li JQ; Tang CQ; Wang H; Ji SZ; Lü KY; Xiao SC; Deng AM; Huang Y; Xia ZF
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1903-6. PubMed ID: 27373357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
    Frakking FN; Rottier WC; Dorigo-Zetsma JW; van Hattem JM; van Hees BC; Kluytmans JA; Lutgens SP; Prins JM; Thijsen SF; Verbon A; Vlaminckx BJ; Cohen Stuart JW; Leverstein-van Hall MA; Bonten MJ
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3092-9. PubMed ID: 23612198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase.
    Peña C; Pujol M; Ardanuy C; Ricart A; Pallarés R; Liñares J; Ariza J; Gudiol F
    J Hosp Infect; 2001 Jan; 47(1):53-9. PubMed ID: 11161899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis.
    Zhu WM; Yuan Z; Zhou HY
    Antimicrob Resist Infect Control; 2020 Jan; 9(1):23. PubMed ID: 32005246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysis: Mortality due to KPC Klebsiella pneumoniae infections.
    Ramos-Castañeda JA; Ruano-Ravina A; Barbosa-Lorenzo R; Paillier-Gonzalez JE; Saldaña-Campos JC; Salinas DF; Lemos-Luengas EV
    J Infect; 2018 May; 76(5):438-448. PubMed ID: 29477802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology, mortality and risk factors for patients with K. pneumoniae bloodstream infections: Clinical impact of carbapenem resistance in a tertiary university teaching hospital of Beijing.
    Zhang G; Zhang M; Sun F; Zhou J; Wang Y; Zhu D; Chen Z; Chen Q; Chang Q; Liu H; Chai W; Pan H
    J Infect Public Health; 2020 Nov; 13(11):1710-1714. PubMed ID: 33082112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Chopra T; Marchaim D; Veltman J; Johnson P; Zhao JJ; Tansek R; Hatahet D; Chaudhry K; Pogue JM; Rahbar H; Chen TY; Truong T; Rodriguez V; Ellsworth J; Bernabela L; Bhargava A; Yousuf A; Alangaden G; Kaye KS
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3936-42. PubMed ID: 22547616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum β-lactamase Klebsiella pneumoniae among cancer patients.
    Li D; Chen Y; Zhang W; Zheng S; Zhang Q; Bai C; Zhang P
    Ir J Med Sci; 2014 Sep; 183(3):463-9. PubMed ID: 24293294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
    Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
    Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
    Paterson DL; Ko WC; Von Gottberg A; Mohapatra S; Casellas JM; Goossens H; Mulazimoglu L; Trenholme G; Klugman KP; Bonomo RA; Rice LB; Wagener MM; McCormack JG; Yu VL
    Clin Infect Dis; 2004 Jul; 39(1):31-7. PubMed ID: 15206050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of related factors of carbapenem resistant Klebsiella pneumoniae infection in patients with artificial airway].
    Bian W; Chen W; Gu X; Wang S; Liu Y; Zhao G; Qin Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1324-1330. PubMed ID: 33463491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Colonization of Carbapenem-Resistant Klebsiella pneumoniae: Epidemiology, Resistance Mechanisms, and Risk Factors in Patients Admitted to Intensive Care Units in China.
    Qin X; Wu S; Hao M; Zhu J; Ding B; Yang Y; Xu X; Wang M; Yang F; Hu F
    J Infect Dis; 2020 Mar; 221(Suppl 2):S206-S214. PubMed ID: 32176790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.